1. Synthesis of cyclic pyranopterin monophosphate, a biosynthetic intermediate in the molybdenum cofactor pathway
- Author
-
Sylvia M. Baars, Jose Angel Santamaria-Araujo, Derek K. Watt, Keith Clinch, Michael Storek, Yas Saotome, Ashish Tiwari, Abdel A. Belaidi, Dixon Rachel Anne, Graeme J. Gainsford, and Günter Schwarz
- Subjects
Stereochemistry ,Hydrobromide ,Pteridines ,Coenzymes ,chemistry.chemical_element ,Stereoisomerism ,Cyclic pyranopterin monophosphate ,Pterins ,chemistry.chemical_compound ,Organophosphorus Compounds ,chemistry ,Sulfite ,Molybdenum ,Drug Discovery ,Metalloproteins ,Swern oxidation ,Escherichia coli ,Molecular Medicine ,Humans ,Hydroxymethyl ,Molybdenum cofactor ,Molybdenum Cofactors ,Signal Transduction - Abstract
Cyclic pyranopterin monophosphate (1), isolated from bacterial culture, has previously been shown to be effective in restoring normal function of molybdenum enzymes in molybdenum cofactor (MoCo)-deficient mice and human patients. Described here is a synthesis of 1 hydrobromide (1·HBr) employing in the key step a Viscontini reaction between 2,5,6-triamino-3,4-dihydropyrimidin-4-one dihydrochloride and D-galactose phenylhydrazone to give the pyranopterin (5aS,6R,7R,8R,9aR)-2-amino-6,7-dihydroxy-8-(hydroxymethyl)-3H,4H,5H,5aH,6H,7H,8H,9aH,10H-pyrano[3,2-g]pteridin-4-one (10) and establishing all four stereocenters found in 1. Compound 10, characterized spectroscopically and by X-ray crystallography, was transformed through a selectively protected tri-tert-butoxycarbonylamino intermediate into a highly crystalline tetracyclic phosphate ester (15). The latter underwent a Swern oxidation and then deprotection to give 1·HBr. Synthesized 1·HBr had in vitro efficacy comparable to that of 1 of bacterial origin as demonstrated by its enzymatic conversion into mature MoCo and subsequent reconstitution of MoCo-free human sulfite oxidase-molybdenum domain yielding a fully active enzyme. The described synthesis has the potential for scale up.
- Published
- 2013